OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Bleichroeder LP

Bleichroeder LP trimmed its holdings in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 269,675 shares of the company's stock after selling 3,775,457 shares during the period. OptiNose accounts for about 0.5% of Bleichroeder LP's investment portfolio, making the stock its 23rd largest position. Bleichroeder LP owned about 2.68% of OptiNose worth $1,801,000 as of its most recent SEC filing.

Separately, Acorn Capital Advisors LLC acquired a new position in shares of OptiNose in the fourth quarter valued at approximately $2,824,000. 85.60% of the stock is currently owned by institutional investors.

Insider Activity at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the transaction, the chief executive officer now directly owns 126,931 shares in the company, valued at $671,464.99. This represents a 4.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 8,213 shares of company stock valued at $43,643. Corporate insiders own 2.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on OPTN shares. Piper Sandler reiterated a "neutral" rating and set a $9.00 target price (down from $15.00) on shares of OptiNose in a research report on Friday, March 21st. HC Wainwright reissued a "neutral" rating and issued a $9.00 target price (down from $18.00) on shares of OptiNose in a research report on Friday, March 21st. Finally, Lake Street Capital lowered shares of OptiNose from a "buy" rating to a "hold" rating and dropped their price target for the stock from $17.00 to $9.00 in a research report on Thursday, March 20th.

OptiNose Price Performance

OPTN stock remained flat at $9.39 during trading on Friday. The company's stock had a trading volume of 8,064 shares, compared to its average volume of 59,578. OptiNose, Inc. has a 1 year low of $4.82 and a 1 year high of $20.03. The firm has a market cap of $95.09 million, a price-to-earnings ratio of -2.24 and a beta of -0.88. The firm's 50-day simple moving average is $8.39 and its 200 day simple moving average is $7.53.

OptiNose (NASDAQ:OPTN - Get Free Report) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.67. The company had revenue of $21.47 million during the quarter, compared to analysts' expectations of $21.02 million. Equities research analysts anticipate that OptiNose, Inc. will post -3.22 EPS for the current year.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.